Cargando…

Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2

Detalles Bibliográficos
Autores principales:	Fang, Zhenhao, Peng, Lei, Lucas, Carolina, Lin, Qianqian, Zhou, Liqun, Yang, Luojia, Feng, Yanzhi, Ren, Ping, Renauer, Paul A., Monteiro, Valter S., Hahn, Anne M., Park, Jonathan J., Zhou, Xiaoyu, Grubaugh, Nathan D., Wilen, Craig B., Chen, Sidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295082/ https://www.ncbi.nlm.nih.gov/pubmed/35853867 http://dx.doi.org/10.1038/s41421-022-00435-w

Ejemplares similares

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
por: Ren, Ping, et al.
Publicado: (2023)

Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
por: Ren, Ping, et al.
Publicado: (2023)

Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
por: Peng, Lei, et al.
Publicado: (2022)

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
por: Peng, Lei, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens
por: Fang, Zhenhao, et al.
Publicado: (2023)

Structural characteristics of the SARS-CoV-2 Omicron lineages BA.1 and BA.2 virions
por: Ma, Xiaoyu, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages
por: Ai, Jingwen, et al.
Publicado: (2022)

Partial ORF1ab Gene Target Failure with Omicron BA.2.12.1
por: Rodino, Kyle G., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2
por: Evans, John P., et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings
por: Ferreira, Victor H., et al.
Publicado: (2022)

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
por: Kang, Sung-Woon, et al.
Publicado: (2023)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
por: Kimura, Izumi, et al.
Publicado: (2022)

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
por: Tamura, Tomokazu, et al.
Publicado: (2023)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
por: Shuai, Huiping, et al.
Publicado: (2023)

Antibody response and cross-neutralization after Omicron BA.2 infection
por: Zhang, Yiwen, et al.
Publicado: (2023)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
por: Moriyama, Miyu, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
por: Torres, Carolina, et al.
Publicado: (2023)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5
por: Arora, Prerna, et al.
Publicado: (2022)

Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
por: Pedersen, Rune M., et al.
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fpb8ks15lnvtksj71iuf6hb2hc